High Response Rate in R/R Multiple Myeloma With Bispecific Antibody

(MedPage Today) -- SAN DIEGO -- More than 70% of patients with heavily pretreated multiple myeloma responded to an investigational bispecific antibody targeting B-cell maturation antigen (BCMA) and CD3, results from a prospective trial showed...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news